Future

2024

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Abbott Laboratories (NYSE: ABT) has continued to demonstrate its resilience and adaptability in the highly competitive and ever-evolving healthcare sector. The <a aria-label="recent quarter's financial results (opens in a new tab)" href="https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2023-results-issues-2024-financial-outlook-302043275.html" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">recent quarter’s financial results</a> for Abbott Laboratories underscore the company’s continued growth trajectory. Despite a challenging macroeconomic environment, the company has surpassed its revenue targets, showcasing a robust growth pattern. <br><br>Its impressive performance is underpinned by the successful deployment of its diversified product portfolio, which continues to gain traction across different market segments.</p> 
<h3 id="abt-q4-eps-in-line-with-expectations-revenue-beat">ABT Q4 EPS in Line with Expectations, Revenue Beat</h3> 
<p>Abbott Laboratories has outperformed on several fronts compared to the pre-set expectations for the quarter. The expectations were an EPS of $1.19 and revenue of $10.17 billion, which were ambitious targets considering the external economic pressures.</p> 
<p>However, the company met these expectations and surpassed them with an <a href="https://tokenist.com/investing/fundamental-analysis-stocks/" rel="dofollow" class="deco-link">EPS</a> of $1.19 and revenue of $10.24 billion for the quarter. This performance highlights the company’s adeptness in navigating market challenges and its commitment to delivering shareholder value. It also reflects positively on the management’s ability to forecast and prepare for market dynamics, ensuring that the company remains ahead of the curve.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking digital asset story.</a></p> 
 </div> 
</div> 
<h3 id="guidance-for-the-future">Guidance for the Future</h3> 
<p>Key focus areas include continued investment in innovation, exploring new market opportunities, and enhancing operational efficiencies. Abbott issued full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/abbott-laboratories-abt-barely-hits-q4-target-with-1-19-eps/">Abbott Laboratories (ABT) Barely Hits Q4 Target with $1.19 EPS</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Abbott Laboratories (ABT) Barely Hits Q4 Target with $1.19 EPS

Table of Contents

Tokenist

Other articles published on Jan 24, 2024

Prominent Analyst Predicts Bitcoin Underperformance in 2024

Best Affordable Cryptocurrency To Buy This Week

Bitcoin and Altcoins: Avalanche (AVAX) Price Movements and Predictions

Bitcoin: Is a recovery in the works?

Fresh Whales Accumulate Ethereum And Spend $2 Million to Buy This Altcoin

Amazon’s AI-Generated Review Summaries: A Double-Edged Sword

Join our free newsletter for daily crypto updates!